ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022
Validation of
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- A Concept for Preoperative and Intraoperative Molecular Imaging and Detection for Assessing Extent of Disease of Solid Tumors.Oncology reviews · 2024Pooled it
- Value of a repeatEuropean journal of nuclear medicine and molecular imaging · 2026Article
- AI lesion tracking in PET/CT imaging: a proposal for a Siamese-based CNN pipeline applied to PSMA PET/CT scans.European journal of nuclear medicine and molecular imaging · 2025Article
- Review
- Biochemical failure-free survival ofScientific reports · 2025Article
- 2023 FDA TIDES (Peptides and Oligonucleotides) Harvest.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Medicinal (Radio) Chemistry: Building Radiopharmaceuticals for the Future.Current medicinal chemistry · 2024Review
- Highlights on Fluorine-containing Drugs Approved by U.S. FDA in 2023.Current topics in medicinal chemistry · 2024Review
- Invited Commentary: Advanced Anatomic and Molecular Imaging in Recurrent Prostate Cancer.Radiographics : a review publication of the Radiological Society of North America, Inc · 2023Article
- Flotufolastat F 18: Diagnostic First Approval.Molecular diagnosis & therapy · 2023Review
- Assessing the accuracy of [EJNMMI research · 2022Article
- Preclinical evaluation and first in human study of AlFrontiers in oncology · 2022Article
- The Value of Multimodality PET/CT Imaging in Detecting Prostate Cancer Biochemical Recurrence.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.